• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    3/10/23 4:36:22 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    SC 13G/A 1 upix_sc13g.htm SC 13G/A upix_sc13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    § 240.13d-1(b), (c), and (d) and AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

     

    (Amendment No. 1)*

     

    UPEXI, INC.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    39959A106

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

     

     

     

    ☐

    Rule 13d-1(c)

     

     

     

     

    ☒

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 2 of 6 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Gene Salkind (1)

     

     

    2

    .

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    94,444 (2)

    6.

    SHARED VOTING POWER

     

    2,352,941 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    94,444 (2)

    8.

    SHARED DISPOSITIVE POWER

     

    2,352,941 (1)

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,447,385 (1) (2)

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    (SEE INSTRUCTIONS)

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    13.56% (3)

     

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

    (1) Includes shares of Common Stock of the Issuer titled Gene and Catherine Salkind as joint tendency with survivor rights.

     

    (2) Includes options for the purchase of 94,444 of the Issuer’s Common Stock exercisable within 60 days.

     

    (3) Based on 17,960,748 shares of Common Stock as reported in the Issuer’s quarterly report as filed with the Commission on February 15, 2023, and 94,444 shares of the Issuer’s Common Stock issuable upon the exercise of options.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 3 of 6 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Catherine Salkind (1)

     

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    2,352,941 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    2,352,941 (1)

     

     9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,352,941

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    (SEE INSTRUCTIONS)

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    13.1% (2)

     

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

    (1) Includes shares of Common Stock of the Issuer titled Gene and Catherine Salkind as joint tenancy with survivor rights.

     

    (2) Based on 17,960,748 shares of Common Stock as reported in the Issuer’s quarterly report as filed with the Commission on February 15, 2023.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 4 of 6 Pages

     

    Item 1.

     

     

     

     

     

     

    (a)

    Name of Issuer: Upexi, Inc.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices:

     

    17129 US Hwy 19 N.

    Clearwater, FL 33764

     

    Item 2.

     

     

     

     

     

     

    (a)

    Name of Person Filing: Gene and Catherine Salkind

     

     

     

     

    (b)

    Address of Principal Business Office or, if none, Residence:

     

    17129 US Hwy 19 N.

    Clearwater, FL 33764

     

     

    (c)

    Citizenship or Place of Organization: United States of America

     

     

     

     

    (d)

    Title of Class of Securities: Common Stock

     

     

     

     

    (e)

    CUSIP Number: 39959A106

     

    Item 3.

    If this statement is filed pursuant to § 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

     

    (a)

    ☐

    Broker or dealer registered under Section 15 of the Act.

     

     

     

     

     

    (b)

    ☐

    Bank as defined in Section 3(a)(6) of the Act.

     

     

     

     

     

    (c)

    ☐

    Insurance company as defined in Section 3(a)(19) of the Act.

     

     

     

     

     

    (d)

    ☐

    Investment company registered under Section 8 of the Investment Company Act of 1940.

     

     

     

     

     

    (e)

    ☐

    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ☐

    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

     

     

     

     

    (i)

    ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

     

     

     

     

    (j)

    ☐

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

     

     

     

     

    (k)

    ☐

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________________.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 5 of 6 Pages

     

    Item 4.

    Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

    (a)

    Amount beneficially owned:

    Gene Salkind  2,447,385

     

     

    Catherine Salkind  2,352,941

     

     

     

     

    (b)

    Percent of class:

    Gene Salkind  13.56%

    Catherine Salkind  13.1%

     

     

     

     

    (c)

    Number of shares as to which the person has:

     

     

    (i)

    Sole power to vote or to direct the vote:

    Gene Salkind 94,444

     

     

     

     

    (ii)

    Shared power to vote or to direct the vote:

    Gene Salkind 2,352,941

    Catherine Salkind 2,352,941

     

     

     

     

    (iii)

    Sole power to dispose or to direct the disposition of:

    Gene Salkind 94,444

     

     

     

     

    (iv)

    Shared power to dispose or to direct the disposition of:

    Gene Salkind 2,352,941

    Catherine Salkind 2,352,941

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

     Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security

     

    Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.

    Certifications.

     

    Not Applicable.

     

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    March 10, 2023

     

    (Date)

     

     

     

    /s/ Gene Salkind

     

    (Signature)

     

     

     

    Gene Salkind

     

    (Name/Title)

     

     

    March 7, 2023

     

    (Date)

     

     

     

    /s/ Catherine Salkind

     

    (Signature)

     

     

     

    Catherine Salkind

     

    (Name/Title)

     

    Attention: Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

     

    Get the next $UPXI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CSO Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 91% to 838,597 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:09:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - UPEXI, INC. (0001775194) (Filer)

    8/20/25 5:00:44 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    8/15/25 5:00:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-1 filed by Upexi Inc.

    S-1 - UPEXI, INC. (0001775194) (Filer)

    8/11/25 7:30:24 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Surpasses 2 Million SOL in its Treasury

    TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today released its periodic update. "July was a game-changing month for Upexi, particularly with respect to accretive capital raises and a resulting drastic increase in our Solana treasury," stated Allan Marshall, Upexi's Chief Executive Officer. "During the month, we raised over $200 million and grew our Solana holdings by over 172% to 2 million SOL. And we continued to generate additional value fo

    8/5/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12th-14th

    TAMPA, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced that management will participate in a fireside chat moderated by Joseph Vafi, Managing Director of Equity Research at Canaccord Genuity LLC, on Wednesday, August 13th at 1:30 p.m. ET at the Canaccord Genuity 45th Annual Growth Conference taking place at the InterContinental in Boston, MA. Presentation details, including a link to the live webcast, can be found below. Canaccord Genuity Conference:Dates: August 12-14, 2025Loc

    7/30/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

    TAMPA, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 83,000 SOL for $16.7 million, or $201.34 per SOL. The purchase brings the Company's holdings to 1.9 million SOL worth over $381 million using the $200.60 spot price of Solana as of 5:00 pm ET yesterday. Allan Marshall, Chief Executive Officer of Upexi, remarked, "The U.S. continues to make progress around digital asset legislation, which has the potential to usher in mass adoption of blockchain technology.

    7/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

    Upexi purchased an additional 100,000 SOL, and anticipates it may generate up to approximately $26 million in annual staking revenue based on current SOL holdingsCompany releases adjusted metrics for enhanced transparency and analysis TAMPA, Fla., July 21, 2025 (GLOBE NEWSWIRE) --  Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 100,000 SOL, bringing its treasury holdings to 1,818,809 SOL worth $331 million. The recent purchase follows the successful closing of a roughly $200 million equity and c

    7/21/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Regains Compliance with NASDAQ

    Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

    12/23/24 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care